An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

NCT03157167 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Kaposi Sarcoma
HIV Infections

Interventions

DRUG: Tc99m-tilmanocept

Sponsor

Navidea Biopharmaceuticals

Collaborators

[object Object]
[object Object]